The prostate cancer patients who carried the RAGE rs2070600 allelic variant A allele were associated with lower risk to develop grade group upgrade, while the RAGE rs1800625 ‘TC + CC’ were associated with perineural invasion and biomedical recurrence in patients with no grade group upgrade. Here, AGER is linked to prostate cancer.